Boehringer Ingelheim acquires Nerio Therapeutics for $1.3bn
Boehringer will integrate Nerio’s preclinical programme into its portfolio.
30 July 2024
30 July 2024
Boehringer will integrate Nerio’s preclinical programme into its portfolio.
The European agency said that Leqembi’s efficacy was “not large enough” to outweigh its safety risks.
Clinical trial trends point to studying combination therapies and lifestyle changes using alternate designs in Alzheimer’s research.
The CHMP recommendation is based on positive results from the Phase IIb EFFISAYIL 2 trial which enrolled 123 patients.
The UK regulator halts the availability of the cancer treatment following a cost-effective pricing dispute.
The decision is based on the data from the Phase III ASC4FIRST clinical trial.
The blood-brain barrier is the biggest hurdle in treating brain diseases, and research on overcoming this challenge is ongoing.
Flagship and its bioplatform companies are entitled to receive milestone payments of up to $720m from GSK.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.